Pub Date : 2020-09-30DOI: 10.23736/S0026-4725.20.05338-4
A. Carrizzo, Francesca Pagano
{"title":"Circulating VEGF and atherosclerosis risk: is it perhaps the case to reevaluate association with the inflammatory state?","authors":"A. Carrizzo, Francesca Pagano","doi":"10.23736/S0026-4725.20.05338-4","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05338-4","url":null,"abstract":"","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"128 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72546353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-30DOI: 10.23736/S0026-4725.20.05349-9
A. Saglietto, F. D’Ascenzo, E. Cavarretta, G. Frati, M. Anselmino, F. Versaci, G. Biondi‐Zoccai, G. D. de Ferrari
BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has rapidly spread globally. Due to different testing strategies, under-detection of positive subjects and COVID-19-related-deaths remains common. Aim of this analysis was to assess the real impact of COVID-19 through the analysis of 2020 Italian all-cause mortality data compared to historical series. METHODS We performed a retrospective analysis of 2020 and 2015-2019 all-cause mortality data released by the Italian National Institute for Statistics (ISTAT) for the time period 'January 1 - March 21'. This preliminary sample included 1,084 Italian municipalities showing at least 10 deaths during the above-mentioned timeframe and an increase in mortality of more than 20% as compared to the previous five years (2015-2019), with a resulting coverage of 21% of Italian population. The difference between 2020 observed and expected deaths (mean of weekly deaths in 2015-2019) was computed, together with mortality rate ratio (MRR) for each of the four weeks following detection of the first autochthonous COVID-19 case in Italy (23 February, 2020 - 21 March, 2020), as well as for this entire timeframe. Subgroup analysis by age groups was also performed. RESULTS Overall MRR was 1.79 [1.75-1.84], with an observed excess mortality of 8,750 individuals in the investigated sample, which in itself outweighs Italian Civil Protection report of only 4,825 COVID-19-related deaths across Italy, as of March 21. Subgroup analysis did not show any difference in mortality rate in '0-14 years' age group, while MRRs were significantly increased in older age groups, in particular in patients >75 years (MRR 1.84 [1.79-1.89]). In addition, week-by-week analysis showed a progressive increase in MRR during this period, peaking in the last week (15 March, 2020 - 21 March, 2020) with an estimated value of 2.65 [2.53-2.78]. CONCLUSIONS The analysis of all-cause mortality data in Italy indicates that reported COVID-19-related deaths are an underestimate of the actual death toll. All-cause death should be seen as the epidemiological indicator of choice to assess the real mortality impact exerted by SARS-CoV-2, given that it also best reflects the toll on frail patient subsets (eg the elderly or those with cardiovascular disease).
{"title":"Excess all-cause mortality during COVID-19 outbreak: potential role of untreated cardiovascular disease.","authors":"A. Saglietto, F. D’Ascenzo, E. Cavarretta, G. Frati, M. Anselmino, F. Versaci, G. Biondi‐Zoccai, G. D. de Ferrari","doi":"10.23736/S0026-4725.20.05349-9","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05349-9","url":null,"abstract":"BACKGROUND\u0000Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has rapidly spread globally. Due to different testing strategies, under-detection of positive subjects and COVID-19-related-deaths remains common. Aim of this analysis was to assess the real impact of COVID-19 through the analysis of 2020 Italian all-cause mortality data compared to historical series.\u0000\u0000\u0000METHODS\u0000We performed a retrospective analysis of 2020 and 2015-2019 all-cause mortality data released by the Italian National Institute for Statistics (ISTAT) for the time period 'January 1 - March 21'. This preliminary sample included 1,084 Italian municipalities showing at least 10 deaths during the above-mentioned timeframe and an increase in mortality of more than 20% as compared to the previous five years (2015-2019), with a resulting coverage of 21% of Italian population. The difference between 2020 observed and expected deaths (mean of weekly deaths in 2015-2019) was computed, together with mortality rate ratio (MRR) for each of the four weeks following detection of the first autochthonous COVID-19 case in Italy (23 February, 2020 - 21 March, 2020), as well as for this entire timeframe. Subgroup analysis by age groups was also performed.\u0000\u0000\u0000RESULTS\u0000Overall MRR was 1.79 [1.75-1.84], with an observed excess mortality of 8,750 individuals in the investigated sample, which in itself outweighs Italian Civil Protection report of only 4,825 COVID-19-related deaths across Italy, as of March 21. Subgroup analysis did not show any difference in mortality rate in '0-14 years' age group, while MRRs were significantly increased in older age groups, in particular in patients >75 years (MRR 1.84 [1.79-1.89]). In addition, week-by-week analysis showed a progressive increase in MRR during this period, peaking in the last week (15 March, 2020 - 21 March, 2020) with an estimated value of 2.65 [2.53-2.78].\u0000\u0000\u0000CONCLUSIONS\u0000The analysis of all-cause mortality data in Italy indicates that reported COVID-19-related deaths are an underestimate of the actual death toll. All-cause death should be seen as the epidemiological indicator of choice to assess the real mortality impact exerted by SARS-CoV-2, given that it also best reflects the toll on frail patient subsets (eg the elderly or those with cardiovascular disease).","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83424094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-30DOI: 10.23736/S0026-4725.20.05329-3
Haim Moti
In the present paper we review data of the efficacy of CRT based on baseline QRS duration and morphology in patients with heart failure due to left ventricle systolic dysfunction. We specifically review data that analyzed men and women separately. The main findings suggest benefit of CRT in patients with baseline LBBB, but not in patients without LBBB. Benefit is directly related to QRS duration at baseline with increasing rates and magnitude of echocardiographic response ( in terms of improvement in ejection fraction and decrease un LV size) and clinical response with increasing baseline QRS. The effect was most pronounced when QRSd was above 150 ms. Among women treated with CRT, similar to men, the benefit is also confined mainly to patients with baseline LBBB. In contrast to men benefit is evident starting with QRSd >130 ms. These findings may suggest that different QRS duration criteria should be used for men and women considered for CRT.
{"title":"Should different ECG-QRSd criteria be used for men and women with heart failure for cardiac resynchronization therapy?","authors":"Haim Moti","doi":"10.23736/S0026-4725.20.05329-3","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05329-3","url":null,"abstract":"In the present paper we review data of the efficacy of CRT based on baseline QRS duration and morphology in patients with heart failure due to left ventricle systolic dysfunction. We specifically review data that analyzed men and women separately. The main findings suggest benefit of CRT in patients with baseline LBBB, but not in patients without LBBB. Benefit is directly related to QRS duration at baseline with increasing rates and magnitude of echocardiographic response ( in terms of improvement in ejection fraction and decrease un LV size) and clinical response with increasing baseline QRS. The effect was most pronounced when QRSd was above 150 ms. Among women treated with CRT, similar to men, the benefit is also confined mainly to patients with baseline LBBB. In contrast to men benefit is evident starting with QRSd >130 ms. These findings may suggest that different QRS duration criteria should be used for men and women considered for CRT.","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79762333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-29DOI: 10.23736/S0026-4725.20.05170-1
K. Filipovic, B. Bellmann, A. Sultan, J. Lüker, T. Plenge, D. Steven
BACKGROUND Hypokalemia has been linked to electrocardiogram changes and afterdepolarization-mediated arrhythmias. However, the association betweeen hypokalemia and atrial fibrillation (AF) has not been well studied. Hydrochlorothiazide (HCT) diuretic therapy was shown to be associated with hypokalemia in multiple studies. We aimed to determine whether HCT therapy is associated with early recurrence of AF after radiofrequency (RF) catheter ablation during a 3 month follow-up. METHODS We performed a retrospective registry analysis of our internal AF ablation registry, containing 807 consecutive patients that underwent RF ablation for symptomatic AF. Propensity score matching was used to match 156 patients on HCT therapy with 156 controls. Furthermore, we performed propensity score matching between the first and the fourth quartile of baseline serum potassium (K) concentrations in the initial population (n=807). RESULTS We observed a small but statistically significant difference in baseline mean potassium levels between the HCT group and the control group (4.03 mmol/l vs. 4.19 mmol/l respectively, p= 0.001). There was no difference in short term recurrence of atrial fibrillation in the HCT group compared to the propensity score matched control group (41.0% (n=64) vs. 45.5% (n=71), p=0.424). In the comparison between the first and the fourth quartile of baseline serum potassium values, no difference in AF recurrence (38.2% (n=63) vs. 37.0% (n=61), p=0.820) during a 3 month follow up after ablation was observed between both groups. CONCLUSIONS Patients on HCT therapy showed no difference in short term recurrence of AF after ablation compared to propensity matched controls.
背景:低钾血症与心电图改变和去极化后介导的心律失常有关。然而,低钾血症与心房颤动(AF)之间的关系尚未得到很好的研究。多项研究表明,氢氯噻嗪(HCT)利尿剂治疗与低钾血症有关。我们的目的是在3个月的随访中确定HCT治疗是否与射频(RF)导管消融后AF的早期复发有关。方法:我们对内部房颤消融登记进行了回顾性登记分析,包括807例连续接受射频消融治疗症状性房颤的患者。倾向评分匹配用于156例HCT治疗患者和156例对照。此外,我们在初始人群(n=807)的基线血清钾(K)浓度的第一个和第四个四分位数之间进行了倾向评分匹配。结果HCT组和对照组的基线平均钾水平差异虽小,但有统计学意义(分别为4.03 mmol/l和4.19 mmol/l, p= 0.001)。与倾向评分匹配的对照组相比,HCT组房颤短期复发率无差异(41.0% (n=64) vs 45.5% (n=71), p=0.424)。在基线血钾值的第一和第四个四分位数的比较中,两组在消融后3个月的随访中房颤复发率无差异(38.2% (n=63) vs 37.0% (n=61), p=0.820)。结论:与倾向匹配的对照组相比,HCT治疗的患者消融后房颤短期复发无差异。
{"title":"Hydrochlorothiazide therapy: impact on early recurrence of atrial fibrillation after catheter ablation?","authors":"K. Filipovic, B. Bellmann, A. Sultan, J. Lüker, T. Plenge, D. Steven","doi":"10.23736/S0026-4725.20.05170-1","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05170-1","url":null,"abstract":"BACKGROUND\u0000Hypokalemia has been linked to electrocardiogram changes and afterdepolarization-mediated arrhythmias. However, the association betweeen hypokalemia and atrial fibrillation (AF) has not been well studied. Hydrochlorothiazide (HCT) diuretic therapy was shown to be associated with hypokalemia in multiple studies. We aimed to determine whether HCT therapy is associated with early recurrence of AF after radiofrequency (RF) catheter ablation during a 3 month follow-up.\u0000\u0000\u0000METHODS\u0000We performed a retrospective registry analysis of our internal AF ablation registry, containing 807 consecutive patients that underwent RF ablation for symptomatic AF. Propensity score matching was used to match 156 patients on HCT therapy with 156 controls. Furthermore, we performed propensity score matching between the first and the fourth quartile of baseline serum potassium (K) concentrations in the initial population (n=807).\u0000\u0000\u0000RESULTS\u0000We observed a small but statistically significant difference in baseline mean potassium levels between the HCT group and the control group (4.03 mmol/l vs. 4.19 mmol/l respectively, p= 0.001). There was no difference in short term recurrence of atrial fibrillation in the HCT group compared to the propensity score matched control group (41.0% (n=64) vs. 45.5% (n=71), p=0.424). In the comparison between the first and the fourth quartile of baseline serum potassium values, no difference in AF recurrence (38.2% (n=63) vs. 37.0% (n=61), p=0.820) during a 3 month follow up after ablation was observed between both groups.\u0000\u0000\u0000CONCLUSIONS\u0000Patients on HCT therapy showed no difference in short term recurrence of AF after ablation compared to propensity matched controls.","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78713823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-29DOI: 10.23736/S0026-4725.20.05211-1
A. Zangrillo, Federica Morselli, Gaetano Lombardi, A. Yavorovskiy, V. Likhvantsev, L. Beretta, F. Monaco, G. Landoni
The interest in percutaneous high tech cardiac procedures has increased in recent years together with its safety and efficacy. In fragile patients, procedural sedation and analgesia are used to perform most of the procedures. General anesthesia remains the technique of choice during the team learning curve and might be required in selected patients or in emergent situations. Despite the high costs of percutaneous high tech cardiac procedures, the decrease in length of hospital stay, rate of intensive care admission and complications, balance the increase in devices costs. In fragile patients who undergo percutaneous high tech cardiac procedures, the primary role of the anesthesiologist is to prevent the need forpostprocedural intensive care unit and complications rate. Starting from the experience of a large university third level hospital we identified the eight most commonly performed contemporary percutaneous high tech cardiac procedures (ventricular tachycardia and atrial fibrillation ablation, protected percutaneous coronary intervention, transcatheter aortic valve implantation, MitraClip®, percutaneous patent foramen ovale closure, left atrial appendage closure, and dysfunctional lead extraction), discuss the role of procedural sedation and analgesia in this setting, and explore future perspectives.
{"title":"Procedural sedation and analgesia for percutaneous high tech cardiac procedures.","authors":"A. Zangrillo, Federica Morselli, Gaetano Lombardi, A. Yavorovskiy, V. Likhvantsev, L. Beretta, F. Monaco, G. Landoni","doi":"10.23736/S0026-4725.20.05211-1","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05211-1","url":null,"abstract":"The interest in percutaneous high tech cardiac procedures has increased in recent years together with its safety and efficacy. In fragile patients, procedural sedation and analgesia are used to perform most of the procedures. General anesthesia remains the technique of choice during the team learning curve and might be required in selected patients or in emergent situations. Despite the high costs of percutaneous high tech cardiac procedures, the decrease in length of hospital stay, rate of intensive care admission and complications, balance the increase in devices costs. In fragile patients who undergo percutaneous high tech cardiac procedures, the primary role of the anesthesiologist is to prevent the need forpostprocedural intensive care unit and complications rate. Starting from the experience of a large university third level hospital we identified the eight most commonly performed contemporary percutaneous high tech cardiac procedures (ventricular tachycardia and atrial fibrillation ablation, protected percutaneous coronary intervention, transcatheter aortic valve implantation, MitraClip®, percutaneous patent foramen ovale closure, left atrial appendage closure, and dysfunctional lead extraction), discuss the role of procedural sedation and analgesia in this setting, and explore future perspectives.","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"19 3-4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78103882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-29DOI: 10.23736/S0026-4725.20.05128-2
J. Kewcharoen, N. Prasitlumkum, S. Titichoatrattana, Chutikarn Wittayalikit, A. Trongtorsak, C. Kanitsoraphan, P. Putthapiban, K. Poonsombudlert, P. Rattanawong, Eugene H. Chung
BACKGROUND Ablation of ventricular tachycardia is the main therapy for patients with drug-refractory VT. Although evidence suggests that VT ablation could lower the incidence of recurrent VT, many cases still develop VT in follow-up. In this study, we performed a systematic review and meta-analysis to examine risk factors for recurrent VT in patients with postinfarction VT who underwent VT ablation. METHODS We comprehensively searched the databases of MEDLINE and EMBASE from inception to March 2020. Included studies were cohort studies, experimental trials, or randomized controlled trials that evaluate the risk of recurrent VT in postinfarction VT patients who underwent VT ablation. Data from each study were combined using random-effects. RESULTS Thirteen studies involving 1,803 postinfarction patients who underwent VT ablation were included. Inducibility after the procedure (pooled HR=1.71, p<0.001), lower baseline left ventricular ejection fraction (LVEF) (pooled HR=0.98, p<0.001) and higher baseline New York Heart Association (NYHA) classification (pooled HR=1.34, p=0.003) were significantly associated with VT recurrence during the follow-up. There was no significant association between age, gender or diabetes mellitus and VT recurrence. CONCLUSIONS Our meta-analysis demonstrated that inducibility after the procedure, lower baseline LVEF and higher baseline NYHA classification were associated with an increased risk of VT recurrence in postinfarction VT patients who underwent VT ablation.
{"title":"Factors associated with recurrent postinfarction ventricular tachycardia following ablation: a meta-analysis.","authors":"J. Kewcharoen, N. Prasitlumkum, S. Titichoatrattana, Chutikarn Wittayalikit, A. Trongtorsak, C. Kanitsoraphan, P. Putthapiban, K. Poonsombudlert, P. Rattanawong, Eugene H. Chung","doi":"10.23736/S0026-4725.20.05128-2","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05128-2","url":null,"abstract":"BACKGROUND\u0000Ablation of ventricular tachycardia is the main therapy for patients with drug-refractory VT. Although evidence suggests that VT ablation could lower the incidence of recurrent VT, many cases still develop VT in follow-up. In this study, we performed a systematic review and meta-analysis to examine risk factors for recurrent VT in patients with postinfarction VT who underwent VT ablation.\u0000\u0000\u0000METHODS\u0000We comprehensively searched the databases of MEDLINE and EMBASE from inception to March 2020. Included studies were cohort studies, experimental trials, or randomized controlled trials that evaluate the risk of recurrent VT in postinfarction VT patients who underwent VT ablation. Data from each study were combined using random-effects.\u0000\u0000\u0000RESULTS\u0000Thirteen studies involving 1,803 postinfarction patients who underwent VT ablation were included. Inducibility after the procedure (pooled HR=1.71, p<0.001), lower baseline left ventricular ejection fraction (LVEF) (pooled HR=0.98, p<0.001) and higher baseline New York Heart Association (NYHA) classification (pooled HR=1.34, p=0.003) were significantly associated with VT recurrence during the follow-up. There was no significant association between age, gender or diabetes mellitus and VT recurrence.\u0000\u0000\u0000CONCLUSIONS\u0000Our meta-analysis demonstrated that inducibility after the procedure, lower baseline LVEF and higher baseline NYHA classification were associated with an increased risk of VT recurrence in postinfarction VT patients who underwent VT ablation.","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78955154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-29DOI: 10.23736/S0026-4725.20.05167-1
M. Golino, Silvia Nuzzo, C. Briguori
Stentys self-apposing stent was designed to face complex lesions in the precincts of percutaneous coronary interventions. Nitinol platform and disconnectable struts were designed to provide a complete apposition on the vessel wall in challenging lesions such as significant tapering, primary angioplasty in ST segment elevation myocardial infarction and bifurcation. Stentys X-Position S is a sirolimus eluting stent with a novel delivery system aiming to improve positioning. Clinical trials showed good results in terms of procedural success rate, clinical outcome and short term strut apposition. Nevertheless, Stentys stent did not show superiority over the conventional balloon-expandable stents in the clinical outcomes. Authors underlined the importance of a learning curve and an adequate training period to get familiar with the device's features. Future trials in an all-comer population using the novel X-Position S stent will confirm the preliminary findings and strengthen evidence in clinical practice.
{"title":"Stentys coronary system: current status and future direction.","authors":"M. Golino, Silvia Nuzzo, C. Briguori","doi":"10.23736/S0026-4725.20.05167-1","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05167-1","url":null,"abstract":"Stentys self-apposing stent was designed to face complex lesions in the precincts of percutaneous coronary interventions. Nitinol platform and disconnectable struts were designed to provide a complete apposition on the vessel wall in challenging lesions such as significant tapering, primary angioplasty in ST segment elevation myocardial infarction and bifurcation. Stentys X-Position S is a sirolimus eluting stent with a novel delivery system aiming to improve positioning. Clinical trials showed good results in terms of procedural success rate, clinical outcome and short term strut apposition. Nevertheless, Stentys stent did not show superiority over the conventional balloon-expandable stents in the clinical outcomes. Authors underlined the importance of a learning curve and an adequate training period to get familiar with the device's features. Future trials in an all-comer population using the novel X-Position S stent will confirm the preliminary findings and strengthen evidence in clinical practice.","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"116 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80743959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-29DOI: 10.23736/S0026-4725.20.05239-1
L. Keen, A. Abbate, V. Clark, F. Moeller, Alex Y. Tan
BACKGROUND Marijuana use increases cardiac sympathetic activity within minutes of its use and this effect may begin to decrease as soon as one hour after marijuana use. However, the cardiovascular effects of marijuana use more than an hour after use is poorly characterized. The purpose of the current study is to compare heart rate, a marker of cardiac sympathetic activity, across recent marijuana use groups (never used=63; recent use [in the past 24 hours; subacute] = 13; in the past 7 days, but not in the past 24 hours = 17). Overall, the current sample included 93 African American/Black college students, with a mean age of 20.03 (SD = 2.21). METHODS Participants completed a demographic form, a brief battery of psychological questionnaires, and had their heart rate assessed at baseline. RESULTS Analysis of covariance showed that heart rate was statistically significantly lower in the recent use group (M = 62.38) compared with the non-users group (M = 73.92). This difference persisted before and after statistically adjusting for demographic covariates. CONCLUSIONS These results suggest that there may be a cardiovascular process that occurs when using marijuana that results in a compensatory, reduced heart rate.
{"title":"Differences in heart rate among recent marijuana use groups.","authors":"L. Keen, A. Abbate, V. Clark, F. Moeller, Alex Y. Tan","doi":"10.23736/S0026-4725.20.05239-1","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05239-1","url":null,"abstract":"BACKGROUND\u0000Marijuana use increases cardiac sympathetic activity within minutes of its use and this effect may begin to decrease as soon as one hour after marijuana use. However, the cardiovascular effects of marijuana use more than an hour after use is poorly characterized. The purpose of the current study is to compare heart rate, a marker of cardiac sympathetic activity, across recent marijuana use groups (never used=63; recent use [in the past 24 hours; subacute] = 13; in the past 7 days, but not in the past 24 hours = 17). Overall, the current sample included 93 African American/Black college students, with a mean age of 20.03 (SD = 2.21).\u0000\u0000\u0000METHODS\u0000Participants completed a demographic form, a brief battery of psychological questionnaires, and had their heart rate assessed at baseline.\u0000\u0000\u0000RESULTS\u0000Analysis of covariance showed that heart rate was statistically significantly lower in the recent use group (M = 62.38) compared with the non-users group (M = 73.92). This difference persisted before and after statistically adjusting for demographic covariates.\u0000\u0000\u0000CONCLUSIONS\u0000These results suggest that there may be a cardiovascular process that occurs when using marijuana that results in a compensatory, reduced heart rate.","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76775516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-25DOI: 10.23736/S0026-4725.20.05372-4
L. Macovei, R. Magopet, G. Campo
{"title":"DES: new presumed effects over in-stent restenosis prevention.","authors":"L. Macovei, R. Magopet, G. Campo","doi":"10.23736/S0026-4725.20.05372-4","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05372-4","url":null,"abstract":"","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89699365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-09-25DOI: 10.23736/S0026-4725.20.05404-3
G. Gasparini, G. Andò, F. Imperadore, L. Santoro, D. Regazzoli
{"title":"Lower extremities arterial disease (LEAD): not a peripheral issue.","authors":"G. Gasparini, G. Andò, F. Imperadore, L. Santoro, D. Regazzoli","doi":"10.23736/S0026-4725.20.05404-3","DOIUrl":"https://doi.org/10.23736/S0026-4725.20.05404-3","url":null,"abstract":"","PeriodicalId":18565,"journal":{"name":"Minerva cardioangiologica","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86705155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}